Blood Research最新文献_第2页

Pseudo Chediak-Higashi anomaly in a diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis. 弥漫性大b细胞淋巴瘤伴噬血细胞性淋巴组织细胞增多症的伪Chediak-Higashi异常。

IF 2.3

Blood Research Pub Date : 2025-01-08 DOI: 10.1007/s44313-024-00052-4

Biyun Yi, Mengying Zeng

引用次数: 0

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations. 复发/难治性慢性淋巴细胞白血病患者全身治疗的相对疗效：基于17p缺失/TP53突变的网络meta分析

IF 2.3

Blood Research Pub Date : 2025-01-02 DOI: 10.1007/s44313-024-00038-2

Jinchul Kim, Jinhyun Cho, Joo Han Lim, Moon Hee Lee

{"title":"Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations.","authors":"Jinchul Kim, Jinhyun Cho, Joo Han Lim, Moon Hee Lee","doi":"10.1007/s44313-024-00038-2","DOIUrl":"10.1007/s44313-024-00038-2","url":null,"abstract":"Purpose: This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p deletion and TP53 mutations.Methods: We conducted a systematic literature review to identify all publicly available randomized controlled trials (RCTs) using PubMed, EMBASE, the Cochrane database, and meeting abstracts published through December 2023. A Bayesian network meta-analysis was performed to estimate the hazard ratios (HRs) for progression-free survival (PFS) with 95% confidence intervals (CIs) and to determine the ranking of the included regimens.Results: Twelve trials involving 4,437 patients and 13 treatment options were included in the meta-analysis. Venetoclax plus rituximab and zanubrutinib emerged as the most effective treatments for the overall R/R CLL population, showing the lowest PFS HR (HR 0.62, 95% CI 0.32-1.20 and HR 0.65, 95% CI 0.49-0.86, respectively) versus ibrutinib, and were ranked as the best agent (surface under the cumulative ranking curve [SUCRA] value of both 90%, respectively) among the included drugs. In the 17p deletion/TP53 mutation subgroup, zanubrutinib demonstrated the most favorable efficacy (HR 0.52, 95% CI 0.31-0.88 versus ibrutinib) with the highest SUCRA value (97%). In patients without these mutations, venetoclax plus rituximab was the most effective (HR 0.49, 95% CI 0.26-0.94 versus ibrutinib) with a SUCRA value of 94%.Conclusion: Our findings highlight the superior efficacy of venetoclax plus rituximab and zanubrutinib for treating R/R CLL and confirm that the role of each regimen may vary depending on the clinically significant mutations.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"60 1","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML. 同源重组修复途径的RAD51和RAD50基因多态性与AML的疾病结局和器官毒性相关。

IF 2.3

Blood Research Pub Date : 2024-12-30 DOI: 10.1007/s44313-024-00033-7

Alireza Mohseni, Gholamreza Toogeh, Shahrbano Rostami, Mohammad Faranoush, Mohammad Jafar Sharifi

{"title":"RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML.","authors":"Alireza Mohseni, Gholamreza Toogeh, Shahrbano Rostami, Mohammad Faranoush, Mohammad Jafar Sharifi","doi":"10.1007/s44313-024-00033-7","DOIUrl":"10.1007/s44313-024-00033-7","url":null,"abstract":"Background: Acute myeloid leukemia (AML) is a heterogeneous malignancy that responds to various therapies. The sensitivity of leukemia cells to chemotherapy is affected by the DNA damage response (DDR). In this study, we examined the association between RAD51 rs1801320, XRCC3 rs861539, NBS1 rs1805794, MRE11 rs569143, and RAD50 rs2299014 variants of the homologous recombination repair (HRR) pathway and AML outcomes.Material and methods: PCR-RFLP was applied for the genotyping of 67 newly diagnosed cases. We performed Sanger sequencing to confirm the results of RFLP genotyping. Outcomes and organ toxicities were collected and χ2 testing was performed for association analysis.Results: RAD50 variant allele carriers were protected from renal and hepatic toxicities (p = 0.024 and p = 0.045, respectively), and were associated with resistant disease (p = 0.001). RAD51 variant alleles were protected from liver toxicity (p = 0.031) and correlated with disease resistance (p = 0.012).Conclusion: RAD50 rs2299014 and RAD51 rs1801320 polymorphisms may be useful for drug adjustment in AML.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"46"},"PeriodicalIF":2.3,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia. 成人严重再生障碍性贫血患者异体造血干细胞移植后恶性肿瘤的发生率和预后。

IF 2.3

Blood Research Pub Date : 2024-12-24 DOI: 10.1007/s44313-024-00046-2

Daehun Kwag, Sung-Soo Park, Sung-Eun Lee, Hee-Je Kim, Jong Wook Lee

{"title":"Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia.","authors":"Daehun Kwag, Sung-Soo Park, Sung-Eun Lee, Hee-Je Kim, Jong Wook Lee","doi":"10.1007/s44313-024-00046-2","DOIUrl":"10.1007/s44313-024-00046-2","url":null,"abstract":"Purpose: This study investigated the occurrence of subsequent malignancies (SM) in adult patients with severe aplastic anemia (SAA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to address the lack of large-scale, long-term data on this complication.Methods: A retrospective cohort analysis of 376 adult patients with SAA who underwent allo-HSCT between 2002 and 2021 at a single center was conducted. The incidence, risk factors, and survival impact of SM were also examined.Results: During the follow-up period, 31 cases of SM (8.2%) were identified. Approximately one-third (32.3%) of SM cases were hematologic malignancies, including post-transplant lymphoproliferative disorder (16.1%), myelodysplastic neoplasm (6.5%), and acute myeloid leukemia (3.2%). Solid tumors accounted for 67.7% of cases, with thyroid cancer being the most prevalent (25.8%). The 15-year cumulative incidence of SM was 11.2%, and the hazard ratio for overall survival according to the development of SM was 16.25 (p < 0.001). High-dose total body irradiation (TBI), anti-thymocyte globulin (ATG), and moderate-to-severe chronic graft-versus-host disease (GVHD) were identified as significant risk factors for subsequent malignancy. Post-transplant SAA patients exhibited a 3.54-fold higher observed cancer incidence than the expected incidence calculated from the age-, sex-, and calendar year-matched general population.Conclusion: SM is a significant long-term complication in patients with posttransplant SAA and has a substantial survival impact. Patients receiving high-dose TBI or ATG, and those with moderate-to-severe chronic GVHD, require vigilant long-term monitoring.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"44"},"PeriodicalIF":2.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for integrating ChatGPT and generative AI into clinical studies. 将ChatGPT和生成式人工智能整合到临床研究中的策略。

IF 2.3

Blood Research Pub Date : 2024-12-24 DOI: 10.1007/s44313-024-00045-3

Jeong-Moo Lee

{"title":"Strategies for integrating ChatGPT and generative AI into clinical studies.","authors":"Jeong-Moo Lee","doi":"10.1007/s44313-024-00045-3","DOIUrl":"10.1007/s44313-024-00045-3","url":null,"abstract":"Large language models, specifically ChatGPT, are revolutionizing clinical research by improving content creation and providing specific useful features. These technologies can transform clinical research, including data collection, analysis, interpretation, and results sharing. However, integrating these technologies into the academic writing workflow poses significant challenges. In this review, I investigated the integration of large-language model-based AI tools into clinical research, focusing on practical implementation strategies and addressing the ethical considerations associated with their use. Additionally, I provide examples of the safe and sound use of generative AI in clinical research and emphasize the need to ensure that AI-generated outputs are reliable and valid in scholarly writing settings. In conclusion, large language models are a powerful tool for organizing and expressing ideas efficiently; however, they have limitations. Writing an academic paper requires critical analysis and intellectual input from the authors. Moreover, AI-generated text must be carefully reviewed to reflect the authors' insights. These AI tools significantly enhance the efficiency of repetitive research tasks, although challenges related to plagiarism detection and ethical use persist.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"45"},"PeriodicalIF":2.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro. 骨髓间充质干细胞外泌体体外抑制急性髓系白血病JAK/STAT信号通路的研究

IF 2.3

Blood Research Pub Date : 2024-12-20 DOI: 10.1007/s44313-024-00051-5

Sahar Jalilivand, Maryam Nabigol, Mehdi Bakhtiyaridovvombaygi, Ahmad Gharehbaghian

{"title":"Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro.","authors":"Sahar Jalilivand, Maryam Nabigol, Mehdi Bakhtiyaridovvombaygi, Ahmad Gharehbaghian","doi":"10.1007/s44313-024-00051-5","DOIUrl":"10.1007/s44313-024-00051-5","url":null,"abstract":"Introduction: Despite advances in the treatment of acute myeloid leukemia (AML), refractory forms of this malignancy and relapse remain common. Therefore, development of novel, synergistic targeted therapies are needed urgently. Recently, mesenchymal stem cells (MSCs) have been shown to be effective in treating various diseases, with most of their therapeutic outcomes attributed to their exosomes. In the current study, we investigated the effects of bone marrow mesenchymal stem cell (BM-MSC) exosomes on the expression of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling genes involved in AML pathogenesis.Material and methods: Exosomes were isolated from BM-MSCs and confirmed using transmission electron microscopy, dynamic light scattering, and flow cytometry. Subsequently, the exosome concentration was estimated using the bicinchoninic acid assay, and HL-60 cells were cocultured with 100 µg/mL of BM-MSC exosomes. Finally, the JAK2, STAT3, and STAT5 expression levels were analyzed using qRT-PCR.Results: The exosome characterization results confirmed that most isolated nanoparticles exhibited a round morphology, expressed CD9, CD63, and CD81, which are specific protein markers for exosome identification, and ranged between 80 and 100 nm in diameter. Furthermore, qRT-PCR analysis revealed a significant downregulation of JAK2, STAT3, and STAT5 in HL-60 cells treated with 100 μg/mL of BM-MSC exosomes.Conclusion: Since JAK/STAT signaling contributes to AML survival, our findings suggest that the downregulation of JAK/STAT genes by BM-MSC exosomes in leukemic cells may aid in designing a potent therapeutic strategy for AML treatment.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"43"},"PeriodicalIF":2.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting. 急性髓性白血病中IDO表达和调节性T细胞的增加：免疫逃逸和治疗靶向的意义

IF 2.3

Blood Research Pub Date : 2024-12-18 DOI: 10.1007/s44313-024-00048-0

Raziyeh Hakak, Behzad Poopak, Ahmad Majd

{"title":"Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting.","authors":"Raziyeh Hakak, Behzad Poopak, Ahmad Majd","doi":"10.1007/s44313-024-00048-0","DOIUrl":"10.1007/s44313-024-00048-0","url":null,"abstract":"Purpose: This study aimed to determine the frequency of regulatory T cells (Tregs) (CD4+/FOXP3+) and indoleamine 2,3-dioxygenase (IDO) expression in patients with acute myeloid leukemia (AML).Methods: This cross-sectional case-control study was conducted between Jan 2022 and Dec 2023. Bone marrow samples were collected from 20 healthy individuals and 15 patients with AML. Flow cytometry, real-time polymerase chain reaction (PCR), and western blotting were used to evaluate the frequency of Treg and IDO expression levels.Results: The Treg percentage among total lymphocytes was lower in the AML group than that in the normal group. However, Treg percentage among T-helper (Th) lymphocytes was significantly higher in the AML group than that in the normal group (p < 0.05). The mean IDO expression in the AML group was significantly higher than that in the normal group (p = 0.004). A significant relationship was observed between IDO expression and Treg percentage among Th lymphocytes in the AML group (correlation = 0.637; p = 0.003). Moreover, western blot analysis showed a significant increase in IDO protein intensity in the AML group compared with that in the control group (p < 0.001). A significant difference was observed between the IDO concentrations in the AML group and that in the control group (p < 0.001). In addition, a significant difference between TGF-β levels in the AML group and those in the control group (p < 0.01) was observed.Conclusion: IDO inhibition using novel IDO inhibitors along with chemotherapy is a promising approach to overcome the immune escape mechanisms in patients with AML, who exhibit increased levels of IDO expression and Tregs.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"42"},"PeriodicalIF":2.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrations. 急性髓性白血病和骨髓增生异常肿瘤：骨髓增生异常相关基因突变和TP53异常的临床意义。

IF 2.3

Blood Research Pub Date : 2024-12-18 DOI: 10.1007/s44313-024-00044-4

Hyunwoo Kim, Ja Young Lee, Shinae Yu, Eunkyoung Yoo, Hye Ran Kim, Sang Min Lee, Won Sik Lee

{"title":"Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrations.","authors":"Hyunwoo Kim, Ja Young Lee, Shinae Yu, Eunkyoung Yoo, Hye Ran Kim, Sang Min Lee, Won Sik Lee","doi":"10.1007/s44313-024-00044-4","DOIUrl":"10.1007/s44313-024-00044-4","url":null,"abstract":"Purpose: The fifth World Health Organization (WHO) classification (2022 WHO) and International Consensus Classification (ICC) of myeloid neoplasms have recently been published. In this study, patients were reclassified according to the revised classification and their prognoses were analyzed to confirm the clinical utility of the new classifications.Methods: We included 101 adult patients, 77 with acute myeloid leukemia (AML) and 24 with myelodysplastic neoplasms (MDS), who underwent bone marrow aspiration and next-generation sequencing (NGS) between August 2019 and July 2023. We reclassified the patients according to the revised criteria, examined the differences, and analyzed the prognosis using survival analysis.Results: According to the 2022 WHO and ICC, 23 (29.9%) patients and 32 (41.6%) patients were reclassified into different groups, respectively, due to the addition of myelodysplasia-related (MR) gene mutations to the diagnostic criteria or the addition of new entities associated with TP53 mutations. The median overall survival (OS) of patients with AML and MR gene mutations was shorter than that of patients in other AML groups; however, the difference was not significant. Patients with AML and TP53 mutation had a significantly shorter OS than the other AML group (p = 0.0014, median OS 2.3 vs 10.3 months). They also had significantly shorter OS than the AML and MR mutation group (p = 0.002, median OS 2.3 vs 9.6 months).Conclusion: The revised classifications allow for a more detailed categorization based on genetic abnormalities, which may be helpful in predicting prognosis. AML with TP53 mutations is a new ICC category that has shown a high prognostic significance in a small number of cases.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"41"},"PeriodicalIF":2.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology. 评估组蛋白H3.1作为急性缺血性卒中的生物标志物：对NETs和卒中病理生理的见解。

IF 2.3

Blood Research Pub Date : 2024-12-03 DOI: 10.1007/s44313-024-00047-1

Suji Park, Jae-Ryong Shim, Ri-Young Goh, Dae-Hyun Kim, Jin-Yeong Han

{"title":"Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology.","authors":"Suji Park, Jae-Ryong Shim, Ri-Young Goh, Dae-Hyun Kim, Jin-Yeong Han","doi":"10.1007/s44313-024-00047-1","DOIUrl":"10.1007/s44313-024-00047-1","url":null,"abstract":"The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivocal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analyses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"40"},"PeriodicalIF":2.3,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to improve AML outcomes? 如何改善AML治疗结果？

IF 2.3

Blood Research Pub Date : 2024-12-02 DOI: 10.1007/s44313-024-00041-7

Taner Tan, Sinem Civriz Bozdag

引用次数: 0